Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Cash from Financing Activities for 6 consecutive years, with $222000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 49.2% to $222000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.4 million through Dec 2025, up 3701.36% year-over-year, with the annual reading at $50.4 million for FY2025, 3701.36% up from the prior year.
  • Cash from Financing Activities hit $222000.0 in Q4 2025 for Lyell Immunopharma, down from $50.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $393.5 million in Q2 2021 to a low of -$531000.0 in Q3 2021.
  • Historically, Cash from Financing Activities has averaged $24.5 million across 5 years, with a median of $862000.0 in 2024.
  • Biggest YoY gain for Cash from Financing Activities was 2089.05% in 2021; the steepest drop was 1617.14% in 2021.
  • Year by year, Cash from Financing Activities stood at $7.4 million in 2021, then plummeted by 88.34% to $863000.0 in 2022, then dropped by 12.05% to $759000.0 in 2023, then plummeted by 42.42% to $437000.0 in 2024, then tumbled by 49.2% to $222000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for LYEL at $222000.0 in Q4 2025, $50.0 million in Q3 2025, and $183000.0 in Q2 2025.